GlassScriptPhysician profile
Wei-Ming Tuan
NPI 1265510705
$1,519.64
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $340 · 2022: $131.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $267.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $239.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $168.52 | 2019 | |
| Eli Lilly and Company | $131.25 | 2022 | |
| Allergan, INC. | $124.39 | 2019 | |
| Akcea Therapeutics, INC. | $121.83 | 2020 | |
| Novo Nordisk INC | $115.07 | 2019 | |
| Amarin Pharma, INC. | $115.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.44 | 2019 | |
| Mallinckrodt Enterprises LLC | $85.05 | 2019 | |
| Scilex Pharmaceuticals INC. | $41.61 | 2019 | |
| Emergent Biosolutions INC. | $12.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei-Ming Tuan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.